

Product Datasheet

GMB-475

Catalog No. **BP-02353** · CAS **2490599-18-1** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0**
· Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PROTAC Bcr-Abl Apoptosis	Research area Cancer
---	--------------------------------

Molecular formula **C₄₃H₄₆F₃N₇O₇S**

Molecular weight **861.9280**

STRUCTURE



DESCRIPTION

GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

BIOLOGICAL ACTIVITY

GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

SOLUBILITY

Soluble in DMSO, not in water

In vitro DMSO : 250 mg/mL

REFERENCES

- [1]. Burslem GM, et al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019 Sep 15;79(18):4744-4753.
- [2]. Ye W, et al. The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants. Front Pharmacol. 2022 Oct 3;13:931772.